Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|OP449||PP2A Activator 7||OP449 is an activator of PP2A via inhibition of SET, which may reduce tumor size and block cell proliferation (PMID: 26563471, PMID: 32569675).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN loss||prostate cancer||sensitive||OP449||Preclinical||Actionable||In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471).||26563471|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|